RE:RE:RE: GLP-1 receptor agonist Hindsight is great!
It was a risk/reward scenario. The expectation was one of the early drugs would get approved, that would have likely encouraged investment in that drug sector and MAYBE THTX could have gobbled up a bit of that. They took the cheapest route to position themselves as a possibility. As we saw things didn't work out that way.
If it had been me, I'd have wanted to see more patients dosed in a focused phase 2b and likely bankrupted the company. They took a cheap option to position at a slim chance of a biggish payoff and didn't get it. Not uncommon in biotech.
jfm1330 wrote: They stopped it after phase I because they were already behind many other companies, Should never have spent money on a phase I on this peptide. Wasted money, but hey, at the time they had plenty of cash and about 30 M shares outstanding.
https://go.gale.com/ps/i.do?id=GALE%7CA267769258&sid=sitemap&v=2.1&it=r&p=EAIM&sw=w&userGroupName=anon%7E7eb08b2f&aty=open-web-entry
LouisW wrote: We all know Ozempic is GLP-1 receptor agonist. Furthermore, Roche acquires Carmot which is focusing on GLP-1 receptor agonist development. Interestingly, when I look into TH’s history, I realized that one molecular in TH’s pipeline in early 2000, TH0318 which is GLP-1 agonist…….what happen to it? Why TH terminate the TH0318 development? Anyone know?